Your browser doesn't support javascript.
loading
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Holmes, Frankie A; Moy, Beverly; Delaloge, Suzette; Chia, Stephen K L; Ejlertsen, Bent; Mansi, Janine; Iwata, Hiroji; Gnant, Michael; Buyse, Marc; Barrios, Carlos H; Silovski, Tajana; Separovic, Robert; Bashford, Anna; Zotano, Angel Guerrero; Denduluri, Neelima; Patt, Debra; Gokmen, Erhan; Gore, Ira; Smith, John W; Loibl, Sibylle; Masuda, Norikazu; Tomasevic, Zorica; Petráková, Katarina; DiPrimeo, Daniel; Wong, Alvin; Martin, Miguel; Chan, Arlene.
Afiliação
  • Holmes FA; Texas Oncology, P.A., US Oncology Research, Houston, TX, USA. Electronic address: faholmesmd@icloud.com.
  • Moy B; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Delaloge S; Institut Gustave Roussy, Villejuif, France.
  • Chia SKL; BC Cancer Agency, Vancouver, BC, Canada.
  • Ejlertsen B; Rigshospitalet, Copenhagen, Denmark.
  • Mansi J; Guy's and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King's College, London, United Kingdom.
  • Iwata H; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.
  • Gnant M; Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
  • Buyse M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
  • Barrios CH; Hospital São Lucas, PUCRS, Porto Alegre, Brazil.
  • Silovski T; Department of Oncology, UHC Zagreb, Zagreb, Croatia.
  • Separovic R; University Hospital for Tumors, University Hospital Center "Sestre Milosrdnice", Zagreb, Croatia.
  • Bashford A; Auckland Hospital, Auckland, New Zealand.
  • Zotano AG; Instituto Valenciano de Oncologia, València, Spain.
  • Denduluri N; Virginia Cancer Specialists, US Oncology Research, Arlington, VA, USA.
  • Patt D; Texas Oncology - Round Rock, US Oncology Research, Austin, TX, USA.
  • Gokmen E; Ege University Faculty of Medicine, Izmir, Turkey.
  • Gore I; Alabama Oncology, Birmingham, AL, USA.
  • Smith JW; Northwest Cancer Specialists, P.C., US Oncology Research, Vancouver, VA, USA.
  • Loibl S; Center for Hematology and Oncology Bethanien, Frankfurt, Germany and German Breast Group, Neu-Isenburg, Germany.
  • Masuda N; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Tomasevic Z; Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
  • Petráková K; Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • DiPrimeo D; Puma Biotechnology Inc., Los Angeles, CA, USA.
  • Wong A; Puma Biotechnology Inc., Los Angeles, CA, USA.
  • Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain.
  • Chan A; Breast Cancer Research Centre-WA & Curtin University, Perth, Australia.
Eur J Cancer ; 184: 48-59, 2023 05.
Article em En | MEDLINE | ID: mdl-36898233
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article